nup186 Antibody

What is NUP188 and why is it important in cellular research?

NUP188 is a component of the nuclear pore complex (NPC), a structure essential for trafficking across the nuclear envelope. Research indicates that NUP188 plays a critical role in proper protein transport into the nucleus . As a significant structural component of approximately 196 kDa, this nucleoporin serves as a valuable marker for studying nuclear transport mechanisms, nuclear envelope integrity, and cellular compartmentalization. Understanding NUP188 function contributes to broader knowledge of cellular regulation, particularly in contexts where nuclear-cytoplasmic transport may be altered, such as cancer, neurodegenerative disorders, and viral infections. The protein is highly conserved, with homologs appearing across eukaryotic organisms, including the fission yeast variant often referred to as nup186 .

What applications are most suitable for NUP188 antibodies?

NUP188 antibodies have demonstrated utility across multiple experimental applications. The primary applications include Western blotting (WB), immunohistochemistry on paraffin-embedded sections (IHC-P), immunocytochemistry/immunofluorescence (ICC/IF), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA) . Each application requires specific optimization considerations:

• For Western blotting: Most NUP188 antibodies perform effectively at dilutions between 1:500-1:2000, with the high molecular weight (196 kDa) necessitating extended transfer times and lower percentage gels.

• For IHC-P: Optimal dilutions typically range from 1:20-1:200, with antigen retrieval methods significantly impacting results .

• For ICC/IF: Concentrations around 4 μg/ml have been validated for paraformaldehyde-fixed cells, with nuclear envelope localization serving as a positive control pattern .

The selection of application should be guided by the specific research question, with consideration for the available validation data for each antibody.

How do I select between polyclonal and monoclonal antibodies for NUP188 detection?

Selecting between polyclonal and monoclonal antibodies for NUP188 detection requires careful consideration of experimental requirements. Most commercially available NUP188 antibodies are rabbit polyclonal , offering advantages including:

• Recognition of multiple epitopes, potentially increasing detection sensitivity

• Greater tolerance to minor protein denaturation or conformational changes

• Typically lower cost and greater availability

• Consistent lot-to-lot reproducibility

• Higher specificity for a single epitope

• Reduced background in certain applications

• Preferable for quantitative studies requiring precise standardization

For initial characterization studies, polyclonal antibodies may offer broader detection capability, while follow-up studies requiring absolute specificity might benefit from monoclonal options. When selecting any antibody, researchers should review validation data showing detection of endogenous levels of total NUP188 in relevant model systems .

What optimization strategies improve NUP188 detection in immunofluorescence studies?

Optimizing NUP188 detection in immunofluorescence requires specific methodological adjustments due to its location in the nuclear pore complex. Effective strategies include:

• Fixation optimization: While paraformaldehyde fixation (4%) works effectively for preserving NUP188 epitopes , a dual fixation approach using a brief methanol treatment (-20°C, 5 minutes) following paraformaldehyde can improve nuclear envelope visualization.

• Permeabilization considerations: Careful titration of detergent concentration is critical—excessive permeabilization may disrupt nuclear envelope integrity, while insufficient permeabilization prevents antibody access.

• Blocking protocol enhancement: Extended blocking (2+ hours) with 5% BSA containing 0.1% Triton X-100 reduces non-specific binding to nuclear and perinuclear structures.

• Primary antibody incubation: Overnight incubation at 4°C with antibody dilutions between 1:100-1:500 typically yields optimal signal-to-noise ratios .

• Signal amplification: For low-abundance detection, implementation of tyramide signal amplification or quantum dot-conjugated secondary antibodies can enhance sensitivity while maintaining specificity.

• Co-staining strategy: Parallel staining with other NPC markers (e.g., NUP98 or NUP153) creates internal validation controls and confirms proper nuclear pore localization.

Verification of nuclear rim staining pattern is essential for confirming specificity, with particular attention to the characteristic punctate distribution around the nuclear envelope.

How can cross-reactivity issues be managed when using NUP188 antibodies in evolutionary studies?

Managing cross-reactivity when studying NUP188 across different species requires systematic approaches to antibody validation and selection. Despite sequence homology, significant variations exist between orthologs, particularly between yeast nup186 and mammalian NUP188 . Researchers should:

• Perform comprehensive sequence alignment analysis of target regions between species of interest, focusing on the antibody's immunogen sequence. Most commercial antibodies target human NUP188, with confirmed reactivity to mouse orthologs in some cases .

• Validate each antibody in the specific species of interest using positive and negative controls:

  • Positive controls: Overexpression systems or tissues known to express the target

  • Negative controls: CRISPR knockout lines, siRNA-depleted samples, or pre-absorption tests

• Consider epitope-specific approaches:

  • For highly conserved regions, existing antibodies may work across species

  • For divergent regions, species-specific antibodies may be required

  • Custom antibody generation against conserved epitopes can enhance cross-species applications

• Implement alternative detection methods to confirm antibody results:

  • Parallel RNA expression analysis

  • Tagged protein expression to validate localization patterns

  • Mass spectrometry validation of immunoprecipitated material

When studying yeast nup186 specifically, researchers should note that antibodies developed against human NUP188 may require extensive validation for cross-reactivity, as the homology is lower than between mammalian orthologs .

What are the most common sources of false positives/negatives in NUP188 immunoblotting experiments?

False results in NUP188 immunoblotting can arise from multiple sources that require specific troubleshooting approaches:

Sources of false negatives:

• Inadequate protein extraction: NUP188's association with the nuclear envelope requires specialized extraction methods. Standard RIPA buffers may yield incomplete extraction.

  • Solution: Utilize nuclear extraction protocols with longer extraction times and mechanical disruption

• Transfer inefficiency: The high molecular weight (196 kDa) of NUP188 results in difficult transfer to membranes .

  • Solution: Implement extended transfer times (1.5-2 hours), lower percentage gels (7-8%), and wet transfer systems

• Epitope masking/destruction: Sample preparation conditions may alter antibody recognition sites.

  • Solution: Test different denaturation conditions and reducing agent concentrations

Sources of false positives:

• Cross-reactivity with similar nucleoporins: Several nucleoporins share structural similarities.

  • Solution: Confirm specificity using knockout/knockdown controls and peptide competition assays

• Non-specific binding: High antibody concentrations can increase background.

  • Solution: Optimize antibody dilutions (typically 1:500-1:2000) and implement stringent blocking (5% BSA rather than milk proteins)

• Sample degradation: Proteolytic fragments may create bands at unexpected molecular weights.

  • Solution: Use fresh samples with complete protease inhibitor cocktails

A validation table comparing antibody performance across extraction methods can significantly improve experimental design:

How should researchers validate newly purchased NUP188 antibodies before experimental use?

Comprehensive validation of NUP188 antibodies is essential before incorporating them into experimental workflows. A systematic validation protocol should include:

• Literature verification: Cross-reference the antibody catalog number with published studies to evaluate previous validation efforts and application suitability .

• Molecular weight confirmation: Verify detection of the expected 196 kDa band in Western blotting. Be aware that post-translational modifications may slightly alter migration patterns .

• Positive control testing: Utilize tissues/cells known to express NUP188, such as human endometrium or SiHa cells, which have been documented to show strong expression .

• Knockdown/knockout validation: Compare antibody signal between wild-type samples and those with depleted NUP188 (siRNA, shRNA, or CRISPR approaches).

• Subcellular localization assessment: Confirm the characteristic nuclear envelope/nuclear pore complex localization pattern through immunofluorescence microscopy .

• Cross-application consistency: Validate performance across multiple techniques (WB, IP, IF) if the antibody will be used in different applications.

• Lot-to-lot validation: Test new lots against previously validated lots to ensure consistent performance, particularly for polyclonal antibodies.

A detailed validation checklist with quantitative acceptance criteria ensures rigorous antibody evaluation:

How does NUP188 expression vary across tissue types and what implications does this have for experimental design?

NUP188 expression demonstrates tissue-specific variation that significantly impacts experimental design decisions. While NUP188 is ubiquitously expressed as a component of the nuclear pore complex, important quantitative and qualitative differences exist:

• Tissue expression patterns: High expression levels are observed in metabolically active tissues with elevated nuclear transport requirements, including:

  • Endometrial tissue (particularly in secretory phase)

  • Rapidly dividing epithelial cells

  • Neuronal tissues with active nucleocytoplasmic transport

• Cell line considerations: Expression levels vary significantly across common research cell lines:

  • SiHa cells demonstrate robust expression suitable for positive controls

  • Primary cells typically show lower expression compared to immortalized lines

  • Expression can be altered by cell cycle phase and differentiation state

These expression patterns necessitate specific experimental design considerations:

Understanding tissue-specific expression patterns is particularly valuable when studying diseases involving altered nuclear transport, where NUP188 levels may serve as both a marker and mechanistic component.

What are the critical considerations when using NUP188 antibodies in co-immunoprecipitation studies of nuclear pore complex dynamics?

Co-immunoprecipitation (Co-IP) studies of nuclear pore complex dynamics using NUP188 antibodies require specialized considerations due to the complex's structural characteristics and NUP188's interactions:

• Extraction conditions: The nuclear pore complex is a highly stable structure resistant to standard lysis conditions. Effective extraction requires:

  • Digitonin-based (0.5-1%) or NP-40-based (0.5-2%) extractions for mild conditions that preserve interactions

  • Careful optimization of salt concentration (150-300mM NaCl range) to maintain specific interactions

  • Limited detergent exposure time to prevent artificial complex dissociation

• Antibody selection criteria:

  • Prefer antibodies validated specifically for immunoprecipitation applications

  • Select antibodies targeting accessible epitopes (N-terminal regions are often more accessible in native conditions)

  • Consider using affinity-purified antibodies to minimize non-specific interactions

• Confirmation strategies:

  • Implement reciprocal Co-IPs with antibodies against known NUP188 interaction partners

  • Use mild crosslinking (0.5-1% formaldehyde) to stabilize transient interactions

  • Include appropriate negative controls (IgG from the same species, non-NPC proteins)

• Interaction validation methodology:

  • Complement Co-IP results with orthogonal techniques (proximity ligation assays, FRET, BioID)

  • Test interactions under various cellular conditions (cell cycle stages, stress responses)

  • Consider native gel electrophoresis to preserve complexes for downstream analysis

• Data interpretation framework:

  • Distinguish between direct and indirect interactions through stringency washes

  • Evaluate stoichiometry of interactions through quantitative western blotting

  • Consider that some interactions may be cell-type specific or condition-dependent

An interaction mapping approach can systematically identify NUP188 protein partners in the nuclear pore complex:

Successful Co-IP studies require meticulous optimization of each step in the protocol, from cell lysis through washing conditions to elution methods.

How can NUP188 antibodies be utilized in studying nuclear envelope pathologies?

NUP188 antibodies provide valuable tools for investigating nuclear envelope pathologies, offering insights into disease mechanisms beyond simple diagnostic markers. Implementation strategies include:

• Laminopathy investigations: Nuclear envelope diseases often display altered nucleoporin distributions and functions.

  • NUP188 antibodies can reveal abnormal nuclear pore complex clustering, which correlates with disease severity in Hutchinson-Gilford Progeria Syndrome

  • Quantitative immunofluorescence using standardized NUP188 staining protocols allows objective assessment of nuclear pore distribution abnormalities

• Cancer biology applications:

  • Altered nucleocytoplasmic transport represents an emerging hallmark in multiple cancer types

  • NUP188 immunohistochemistry can identify nuclear envelope irregularities in tumor samples

  • Changes in NUP188 distribution patterns may serve as prognostic indicators independent of simple expression levels

• Neurodegenerative disease research:

  • Nuclear pore complex dysfunction is implicated in several neurodegenerative conditions

  • Age-related changes in NUP188 organization correlate with impaired nuclear transport

  • Co-localization studies between NUP188 and disease-associated proteins provide mechanistic insights

• Cellular senescence studies:

  • NUP188 antibodies can track age-associated changes in nuclear pore complex structure

  • Quantitative image analysis of immunofluorescence patterns reveals subtle alterations in nuclear envelope organization

Implementation of these approaches requires:

• Standardized staining protocols with appropriate controls

• Advanced imaging techniques (super-resolution microscopy, electron microscopy)

• Quantitative image analysis algorithms for objective assessment

• Correlation with functional nuclear transport assays

For clinical research applications, tissue microarray analysis using validated NUP188 antibodies can efficiently screen large cohorts for nuclear envelope abnormalities, generating statistical power to identify associations with disease progression and treatment response.

What considerations are important when designing multiplex immunofluorescence protocols incorporating NUP188 antibodies?

Designing effective multiplex immunofluorescence protocols with NUP188 antibodies requires strategic planning to overcome technical challenges while maximizing information yield:

• Antibody compatibility assessment:

  • Host species considerations: Select primary antibodies from different host species to avoid cross-reactivity

  • When using multiple rabbit antibodies (common for NUP188) , implement sequential staining with thorough blocking between rounds

  • Validate each antibody individually before combining to establish baseline staining patterns

• Fluorophore selection strategy:

  • Choose spectrally distinct fluorophores with minimal overlap

  • Consider signal intensity matching—NUP188 typically produces defined but relatively low-intensity nuclear rim staining

  • Assign brighter fluorophores (Alexa 488, 555) to less abundant targets and more photostable fluorophores to targets requiring extended imaging

• Protocol optimization parameters:

  • Fixation: Standard paraformaldehyde (4%) works well for NUP188 while maintaining compatibility with most other targets

  • Antigen retrieval: Heat-induced epitope retrieval methods must be compatible with all targets

  • Blocking: Extended blocking (5% BSA, 2+ hours) reduces background without compromising specific signals

• Multiplexing approaches:

  • Sequential staining: For maximum flexibility but increased time investment

  • Simultaneous staining: Faster but requires rigorous antibody compatibility testing

  • Tyramide signal amplification: Enables use of multiple same-species antibodies but requires careful protocol optimization

• Validation requirements:

  • Single-stained controls for each target to verify signal specificity

  • Fluorophore minus one (FMO) controls to detect spectral overlap

  • Absorption controls to confirm antibody specificity

Example multiplexing panel for nuclear envelope studies:

This approach enables simultaneous analysis of nuclear pore complex structure, nuclear envelope integrity, and their relationship to cellular processes like DNA damage response.